These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 35219090)

  • 1. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
    Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
    Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis.
    Chang L; Zhang X; He L; Ma Q; Fang T; Jiang C; Ma Z; Li Q; Wu C; Tao J
    Oncologist; 2023 Dec; 28(12):e1198-e1208. PubMed ID: 37294663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis.
    Nader-Marta G; Monteforte M; Agostinetto E; Cinquini M; Martins-Branco D; Langouo M; Llombart-Cusac A; Cortés J; Ignatiadis M; Torri V; Apolone G; Cappelletti V; Pruneri G; de Azambuja E; Di Cosimo S
    ESMO Open; 2024 Mar; 9(3):102390. PubMed ID: 38460249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA as prognostic markers of relapsed breast cancer: a systematic review and meta-analysis.
    Guo N; Zhou Q; Chen X; Zeng B; Wu S; Zeng H; Sun F
    J Natl Cancer Cent; 2024 Mar; 4(1):63-73. PubMed ID: 39036387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.
    Rothé F; Silva MJ; Venet D; Campbell C; Bradburry I; Rouas G; de Azambuja E; Maetens M; Fumagalli D; Rodrik-Outmezguine V; Di Cosimo S; Rosa D; Chia S; Wardley A; Ueno T; Janni W; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C; Dawson SJ; Ignatiadis M
    Clin Cancer Res; 2019 Jun; 25(12):3581-3588. PubMed ID: 30862692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis.
    Guo K; Lu J; Lou Y; Zheng S
    Ther Adv Med Oncol; 2023; 15():17588359231177008. PubMed ID: 37256023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Circulating Tumor DNA Dynamics Predict Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases: A Prospective Study.
    Wang XY; Zhang R; Han JH; Chen SQ; Zhao FL; Chen H; Lin J; Fan J; Zhu WW; Lu L; Chen JH
    Ann Surg Oncol; 2023 Aug; 30(8):5252-5263. PubMed ID: 37202570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
    Lin PH; Wang MY; Lo C; Tsai LW; Yen TC; Huang TY; Huang WC; Yang K; Chen CK; Fan SC; Kuo SH; Huang CS
    Front Oncol; 2021; 11():736769. PubMed ID: 34868925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
    Lu J; Feng Y; Guo K; Sun L; Ruan S; Zhang K
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):25. PubMed ID: 38252173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
    Crupi E; de Padua TC; Marandino L; Raggi D; Dyrskjøt L; Spiess PE; Sonpavde GP; Kamat AM; Necchi A
    Eur Urol Oncol; 2024 Feb; 7(1):44-52. PubMed ID: 37330413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor DNA and Survival in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Dickinson K; Sharma A; Agnihotram RV; Altuntur S; Park M; Meterissian S; Burnier JV
    JAMA Netw Open; 2024 Sep; 7(9):e2431722. PubMed ID: 39235812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis.
    Gögenur M; Hadi NA; Qvortrup C; Andersen CL; Gögenur I
    Ann Surg Oncol; 2022 Dec; 29(13):8666-8674. PubMed ID: 35933546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient's Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis.
    Liu H; Lv L; Gao H; Cheng M
    Comput Math Methods Med; 2021; 2021():7545091. PubMed ID: 35003324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update of clinical value of circulating tumor DNA in esophageal cancer: a systematic review and meta-analysis.
    Zhang Y; Du H; Wang N; Wang L; Huang Y
    BMC Cancer; 2024 Jan; 24(1):129. PubMed ID: 38267901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
    Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of post-operative ctDNA detection with outcomes of patients with early breast cancers.
    Cutts R; Ulrich L; Beaney M; Robert M; Coakley M; Bunce C; Crestani GW; Hrebien S; Kalashnikova E; Wu HT; Dashner S; Sethi H; Aleshin A; Liu M; Ring A; Okines A; Smith IE; Barry P; Turner NC; Garcia-Murillas I
    ESMO Open; 2024 Sep; 9(9):103687. PubMed ID: 39216186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.